Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 33, 2014, Pages 12181-12186

  Zhang, Rui ^a   Yang, Jiyuan ^a   Sima, Monika ^a   Zhou, Yan ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Dual isotope label; EPR effect; Macromolecular therapeutics

Indexed keywords

GEMCITABINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE M PHASE; CELL DIVISION; CELL GROWTH; CELL MIGRATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; SYNTHESIS;

DUAL-ISOTOPE LABEL; EPR EFFECT; MACROMOLECULAR THERAPEUTICS;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906316162     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1406233111     Document Type: Article

References (39)

1. Kopeček J (2013) Polymer-drug conjugates: Origins, progress to date and future directions. Adv Drug Deliv Rev 65(1):49-59.
2. Kopeček J (2010) Biomaterials and drug delivery: Past, present, and future. Mol Pharm 7(4):922-925.
3. Kopeček J, Kopečková P (2010) HPMA copolymers: Origins, early developments, present, and future. Adv Drug Deliv Rev 62(2):122-149.
4. Vasey PA, et al.; Cancer Research Campaign Phase I/II Committee (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 5(1):83-94. (Pubitemid 29045181)
5. Seymour LW, et al.; Cancer Research Campaign Phase I/II Clinical Trials committee (2002) Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20(6):1668-1676. (Pubitemid 34260549)
6. Seymour LW, et al. (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34(6):1629-1636.
7. Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 21(5):797-802.
8. Seymour LW, Duncan R, Strohalm J, Kopeček J (1987) Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 21(11):1341-1358.
9. Shiah JG, et al. (2001) Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer 37(1):131- 139.
10. Yang J, Luo K, Pan H, Kopečková P, Kopeček J (2011) Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelicPolyHPMA conjugates. React Funct Polym 71(3):294-302.
11. Luo K, Yang J, Kopečková P, Kopeček J (2011) Biodegradable multiblock poly[N-(2-hydroxypropyl)methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry. Macromolecules 44(8):2481-2488.
12. Pan H, Yang J, Kopečková P, Kopeček J (2011) Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules 12(1):247-252.
13. American Cancer Society (2012) Cancer Facts and Figures 2012 (American Cancer Society, Atlanta).
14. Mutch DG (2003) Gemcitabine combination chemotherapy of ovarian cancer. Gynecol Oncol 90(2 Pt 2):S16-S20.
15. Ozols RF (2000) Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 27(3, Suppl 7):3-7.
16. Lee JH, Kopečková P, Kopeček J, Andrade JD (1990) Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings. Biomaterials 11(7):455-464. (Pubitemid 20329103)
17. Omelyanenko V, Kopečková P, Gentry C, Kopeček J (1998) Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 53(1-3):25-37. (Pubitemid 28218687)
18. Minko T, Kopečková P, Kopeček J (1999) Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res 16(7):986-996. (Pubitemid 29368143)
19. Oliveras-Ferraros C, et al. (2008) Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. Int J Oncol 32(1):113-120. (Pubitemid 351176068)
20. Kroep JR, et al. (2000) Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 83(8):1069-1076.
21. Sui M, Xiong X, Kraft AS, Fan W (2006) Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 5(8):1015-1021.
22. Zupi G, et al. (2005) Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 4(8):866-871.
23. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
24. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56(9):2112-2115. (Pubitemid 26119912)
25. Beumer JH, et al. (2008) Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol 62(3):457-464.
26. Rejmanová P, Kopeček J, Duncan R, Lloyd JB (1985) Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 6(1):45-48. (Pubitemid 15154390)
27. Huang B, Wang W, Bates M, Zhuang X (2008) Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy. Science 319(5864):810-813. (Pubitemid 351225870)
28. Immordino ML, et al. (2004) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100(3):331-346. (Pubitemid 39572916)
29. Fossella FV, et al. (1997) Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15(1):310-316. (Pubitemid 27020589)
30. Von Hoff DD, et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 29(34):4548-4554.
31. Kroep JR, et al. (1999) Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17(7):2190-2197. (Pubitemid 29318852)
32. Saif MW (2013) U.S. Food and Drug Administration approves paclitaxel proteinbound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP 14(6):686-688.
33. De Pas T, et al. (2006) A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer 54(3):359-364. (Pubitemid 44634146)
34. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20(3):449-453.
35. Yan S, Sloane BF (2003) Molecular regulation of human cathepsin B: Implication in pathologies. Biol Chem 384(6):845- 854.
36. Szpaderska AM, Frankfater A (2001) An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61(8):3493- 3500.
37. Nishikawa H, et al. (2004) The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol 92(3):881-886. (Pubitemid 38251392)
38. Minko T, Kopečková P, Pozharov V, Kopeček J (1998) HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54(2):223-233. (Pubitemid 28342701)
39. Carney PL, Rogers PE, Johnson DK (1989) Dual isotope study of iodine-125 and indium-111-labeled antibody in athymic mice. J Nucl Med 30(3):374-384. (Pubitemid 19077328)